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PERSPECTIVE
A systems biology approach towards
understanding and treating non-neovascular
age-related macular degeneration
James T. Handa1, Cathy Bowes Rickman2, Andrew D. Dick3,4,
Michael B. Gorin 5,6, Joan W. Miller 7, Cynthia A. Toth2, Marius Ueffing8,
Marco Zarbin9 & Lindsay A. Farrer10
Age-related macular degeneration (AMD) is the most common cause of blindness among the
elderly in the developed world. While treatment is effective for the neovascular or “wet” form
of AMD, no therapy is successful for the non-neovascular or “dry” form. Here we discuss the
current knowledge on dry AMD pathobiology and propose future research directions that
would expedite the development of new treatments. In our view, these should emphasize
system biology approaches that integrate omic, pharmacological, and clinical data into
mathematical models that can predict disease onset and progression, identify biomarkers,
establish disease causing mechanisms, and monitor response to therapy.
Age-related macular degeneration (AMD) is the world’s leading cause of blindness amongthe elderly1. It is projected that the number of people with AMD worldwide will be 196million in 2020, increasing to 288 million in 2040, with the pooled prevalence of early,
late, and any AMD to be 8.01% (95% CI 3.98–15.49), 0.37% (0.18–0.77), and 8.69% (4.26–17.40),
respectively1. While AMD is currently more prevalent in Europe and North America than Asia,
given that Asia accounts for more than 60% of the world’s population, the largest projected
number of AMD cases will occur in Asia1. In the US alone, approximately 11 million people have
AMD, a prevalence that is similar to that of all invasive cancers combined, and more than double
of that of Alzheimer’s disease2.
AMD is classified into two forms, a non-neovascular or “dry” form and a neovascular or “wet”
form (Fig. 1). In the wet form, rapid, severe vision loss can occur due to the development of new
blood vessels from the choroid into the subretinal space, within Bruch’s membrane, or in the
subretinal pigmented epithelial (RPE) space that can leak fluid, hemorrhage, and with time,
develop fibrosis around these neovascular tufts. In dry AMD, vision loss is typically gradual. Dry
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AMD is defined clinically by the presence of at least intermediate-
size yellow sub-RPE deposits called drusen (63 µm or larger in
diameter), RPE pigmentary abnormalities, and subretinal deposits
called reticular pseudodrusen3. These pigmentary abnormalities
are the clinical manifestation of RPE degeneration, which can
ultimately culminate in death of the RPE and of the overlying
photoreceptors. Multiple medium-sized drusen, large-sized dru-
sen, RPE pigmentary changes, and AMD duration are indepen-
dent risk factors for developing late AMD3. In late, dry AMD or
geographic atrophy (GA), patches of RPE cell loss become con-
fluent. When GA involves the fovea, vision loss is severe.
While successful treatment using anti-vascular endothelial cell
growth factor treatment is available for wet AMD4, no effective
prevention or treatment is available for dry AMD. The Age-
related Eye Disease Study (AREDS) trials demonstrated that
antioxidant micronutrient supplements given to intermediate
AMD patients modestly reduced the risk of developing advanced
disease, and in particular, wet AMD5,6. Recently, lampalizumab,
an inhibitor against complement Factor D, showed some efficacy
in slowing GA progression in a Phase 2 study7, but this result was
not confirmed in a Phase 3 study. A Phase 2 study conducted by
Apellis using an inhibitor of complement factor 3 activation
(APL-2) demonstrated a reduction in the rate of GA progression
but was also associated with an increased risk of wet AMD in a
subset of patients8. A number of other approaches for treating
GA have failed in human trials (e.g., visual cycle inhibitors,
emixustat, Acucela, sustained release of neurotrophic factors,
NT501, Neurotech, and complement pathway inhibitors, eculi-
zumab, Soliris)7,9.
The lack of preventive measures and treatment for dry AMD
underscores the importance of gaining a better understanding of
its pathobiology. Prior research has implicated strong roles for
inflammation, and complement in particular, mitochondrial
dysfunction, oxidative stress, lipid abnormalities, and cell death in
dry AMD pathobiology, but their precise mechanisms are
unclear. Furthermore, the relative magnitude and temporal con-
tributions of these factors remain elusive. Due to the multi-
factorial etiology, effective management of dry AMD may require
multiple targets that differ for prevention and therapy of early,
intermediate, and late stage disease. These targets will likely result
from the elucidation of the mechanistic pathways that are criti-
cally involved at each disease stage. The National Advisory Eye
Council established a working group to evaluate the current
knowledge on dry AMD pathobiology and propose future
research directions that would expedite the development of new
treatments and the purpose of this perspective is to report on the
findings from this working group. The intention is to raise
awareness of the impact of AMD on public health, review the
current understanding of the pathobiology of this disease, offer
future research directions that focus on unbiased systems
approaches, encourage the continued efforts of dedicated vision
scientists who focus on dry AMD, and encourage the broader
scientific community to join in a collaborative effort to develop
therapies for this complex and debilitating disease.
Hallmark pathological changes in dry AMD
The macula is the central area of the retina, 6 mm in diameter,
which contains more than one layer of ganglion cell nuclei
(Fig. 2). The central macula or fovea, 0.8 mm in diameter, is cone-
dominated while the surrounding parafovea is rod-dominated. In
the normal aging parafovea, the RPE become enlarged and often
multinucleated10. In early, dry AMD, parafoveal rods die before
either the RPE or cones11. With advancing dry AMD, the RPE
degenerates with severe changes in cell shape, often becoming
multilayered, and dissociated from Bruch’s membrane with
migration into the retina or below Bruch’s membrane12. These
changes suggest that RPE dysfunction has a central role in the
development of photoreceptor loss in dry AMD.
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Fig. 1 Spectrum of AMD. a Fundus photograph of a normal left macula. Arrowhead points to the fovea. b Right eye with intermediate, dry AMD. Arrowhead
points to a typical large druse while arrow points to RPE hyperpigmentation. c Right eye with geographic atrophy. Arrowheads outline the area of GA.
d Right eye with neovascular AMD. Arrowheads outline the area of choroidal neovascularization that is partially outlined by subretinal hemorrhage
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Coincident with RPE changes, Bruch’s membrane develops
basal deposits or accumulations of heterogeneous debris12. With
aging, the inner Bruch’s membrane accumulates apolipoprotein
B100-containing lipoproteins13, which stimulate inflammatory
infiltration, accumulation of cellular debris, and the formation of
basal deposits. Basal laminar deposits accumulate between the
RPE and its basement membrane, and are associated with dry
AMD when they become thick and composed of heterogeneous
debris. Basal linear deposits, which form within Bruch’s mem-
brane’s inner collagenous layer, are specific to dry AMD.
Nodular-shaped basal linear deposits and focal basal laminar
deposits accumulations are visualized as soft drusen on
clinical exam.
The choriocapillaris is the sinusoidal capillary network of the
choroidal circulation that is adjacent to Bruch’s membrane.
Choriocapillaris endothelium has fenestrations that enable the
bidirectional movement of fluid and macromolecules with the
RPE and outer retina. Early dry AMD is characterized by loss of
the choriocapillaris, which provides oxygen and nutrients for RPE
and photoreceptor survival. Choriocapillaris loss precedes RPE
atrophy and correlates with drusen size and density, thus impli-
cating choriocapillaris dysfunction in RPE survival and druse-
nogenesis14. Finally, reticular pseudodrusen are extracellular
deposits that accumulate in the subretinal space. While initially
overlooked, improved imaging has shown that reticular pseudo-
drusen are part of a continuum of pathology that is referred to as
subretinal drusenoid deposits (SDDs). The presence and pro-
gression of SDD can predict disease advancement to GA15.
Stressors and pathways implicated in dry AMD pathobiology
Oxidative stress. Photoreceptors and the RPE have high meta-
bolic activity that results in reactive oxygen species (ROS) gen-
eration. The high metabolic demand requires a high oxygen
partial pressure of 70–90mmHg16, and the unique, photo-
oxidative stress from light exposure make the macula a high
oxidative stress microenvironment. In addition, several lifestyle
choices such as cigarette smoking, and high fat or high glycemic
index diets, add to the oxidative stress burden, and are associated
with AMD risk17–19. The AREDS trials showed that, among
patients with intermediate AMD, antioxidants lower the risk of
developing advanced AMD5,6. Finally, genetic variants in oxida-
tive stress-related genes, including MTND2*LHON-4917G,
NADH subunits, SOD2, and PPARGC1A, are associated with
AMD risk20–22.
Lipids. Because lipids can occupy more than 40% of drusen
volume23, and polymorphisms in several lipid-related genes,
including LIPC, CETP, ABCA1, and APOE, are associated with
AMD risk24–27, lipids play a critical role in drusenogenesis. The
RPE accumulates cholesterol either from phagocytosis of photo-
receptor outer segments or from the ingestion of lipoproteins
from the circulation. The RPE recycles cholesterol back to the
photoreceptor or eliminates it through reverse cholesterol trans-
port by effluxing cholesterol to ApoAI-I to form a high-density
lipoprotein (HDL)28. With lipoproteinemia, lipoprotein ingestion
is excessive, and the RPE becomes cholesterol-overloaded. Should
the reverse cholesterol transport fail, the RPE will secrete
apoB100 lipoproteins into Bruch’s membrane13,29. With aging,
Bruch’s membrane accumulates advanced glycation endproducts,
which induces lipoprotein lipase, causing the retention and oxi-
dation of lipoproteins30,31. Hydroxyapatite surrounds the oxi-
dized lipoproteins, which get coated with lipids and inflammatory
proteins to promote drusen growth32. Since cones contain more
cholesterol than rods, drusen tend to accumulate in the cone-rich
fovea33.
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Fig. 2 Histological cross-section of a human macula. a Normal macula. b Hard drusen (*) within Bruch’s membrane. c A soft druse (*) within Bruch’s
membrane. (b and c are courtesy of Philip Luthert, MBBS, UCL Institute of Ophthalmology.) d Subretinal drusenoid deposits (SDDs) between shortened
photoreceptor outer segments and the RPE. Arrows highlight one of several SDDs (Courtesy of Christine Curcio, Ph.D., University of Alabama Birmingham
and Project MACULA AMD Histopathology resource (http://projectmacula.cis.uab.edu/). HFL Henle fiber layer, NFL nerve fiber layer, GCL ganglion cell
layer, IPL inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer, POS photoreceptor outer segment, RPE retinal
pigment epithelium, BM Bruch’s membrane. Bar= 25 μm
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SDDs contain unesterified cholesterol and apoE, which
suggests that HDLs are involved in their formation34,35.
Photoreceptors and the RPE have an active bidirectional
cholesterol transport where HDLs accumulate cholesterol
released into the subretinal space and cycles cholesterol between
the RPE and photoreceptors28. With RPE dysfunction,
cholesterol-laden HDLs accumulate in the subretinal space,
triggering inflammation, and the accumulation of complement
factors, vitronectin, and immune cells36. Figure 3 summarizes the
role of lipids in AMD lesion formation.
Inflammation and innate immunity. Altered immune responses
that lead to destructive neuroinflammation are thought to con-
tribute to the dry AMD phenotype. Parainflammation is a low-
grade cytoprotective adaptation to local stress that is intermediate
between immune-mediated homeostasis and chronic inflamma-
tion that maintains cellular and tissue function. Loss of parain-
flammation control contributes to dry AMD by invoking a
chronic, heightened immune response that causes tissue
destruction. The hallmarks of immune activation include drusen
formation, subretinal and choroidal recruitment of microglia/
macrophages, mast cell activation, and RPE immune activation37–
39. This immune activation may involve close interplay between
intracellular complement regulation and NLRP3 assembly in
either immune cells or the RPE, although a recent study argues
against NLRP3 inflammasome activation in the RPE40. At pre-
sent, it is unclear at what point such immune activation converts
from being protective to pathologic41,42. Figure 4 is a schema of
the role of inflammation in AMD pathobiology.
Complement system. Genetic studies have identified comple-
ment pathway gene variants with AMD risk, which strongly
implicates the complement pathway in driving AMD progression.
However, the assumption that these variants induce excessive
complement activation that leads to tissue injury remains unva-
lidated. For example, the exact mechanism for how the comple-
ment factor H (CFH) 402H variant contributes to dry AMD has
eluded researchers for over a decade. CFH acts as both a cofactor
during Factor I-mediated C3b cleavage and as a decay accel-
erating agent against the alternative pathway C3-convertase. The
402H variant increases complement activity43. However, it is
unclear whether this increased activity induces elements of the
dry AMD phenotype because CFH 402H also has impaired
interaction with C-reactive protein, malondialdehyde, and
heparan sulfate proteoglycans that can increase inflammation and
lipoprotein accumulation43–45. As a mechanistic understanding
of the causal molecular pathways is incomplete, perhaps not
surprisingly, clinical trials testing complement inhibitors have
failed9.
Mitochondrial dysfunction. While age-associated mitochon-
drial dysfunction reduces cytoprotective pathway function,
mitochondrial impairment severe enough to cause tissue
damage will herald disease. In dry AMD, RPE mitochondrial
mass is reduced, mitochondria are morphologically abnormal,
and mitochondrial DNA (mtDNA) damage increases with
disease severity46,47. In early and dry AMD, before a patient
loses vision, mtDNA damage in genes involved in electron
transport complex I, II, IV, and V in the RPE accumulates more
in the macula than in the periphery, and occurs in the RPE
prior to the neurosensory retina47–49. With mitochondrial loss
and injury, the RPE has reduced baseline oxygen consumption
and reserve capacity, and elevated ROS, making them poorly
responsive to stress50. This change results in decreased ATP
production, compromised calcium- and ROS-mediated
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signaling, and altered nucleotide metabolism, amino acid, lipid,
and heme biosynthesis, which subsequently impair essential
cytoprotective or specialized functions51. In addition, mito-
chondrial damage can activate apoptosis, leading to RPE
degeneration and death, two key features of AMD.
Cell death. Photoreceptor cell death is the basis for permanent
visual decline in dry AMD. Therefore, identifying the mechan-
isms involved in photoreceptor death is critical for developing
new treatments to prevent permanent visual loss. Photoreceptor
cell death is principally caused by apoptosis and necrosis52.
Preventing photoreceptor cell death by specifically blocking
apoptosis has been unsuccessful when inhibiting caspase because
photoreceptor death is also caused by receptor-interacting protein
kinase (RIPK)-mediated necrosis53. Likewise, when RIPK is
inhibited, photoreceptor loss is unaffected53. In contrast, inhi-
biting both RIPK and caspases impairs both necrosis and apop-
tosis and rescues photoreceptors53. The mechanisms for RPE cell
death may differ from those of photoreceptors. Double stranded
RNA (dsRNA), a component of drusen, is a ligand for Toll-like
Receptor-3, which mediates the innate immune response and cell
death. After injecting dsRNA into the eye, photoreceptors die by
apoptosis and RPE cells die by necrosis54. Since cell death path-
ways are redundant and complementary, combination therapies
that block both apoptosis and necrosis may be effective for
dry AMD.
Strategies for understanding dry AMD etiology and
pathogenesis
Genetics and genomics. Genetic approaches have contributed
enormously to our understanding of AMD pathobiology. The
association of APOE variants with AMD was the first indication
that a specific gene affected disease risk55,56. The advent of high-
throughput technologies and agnostic genome-wide searches
using family-based linkage and genome-wide association study
(GWAS) approaches facilitated the identification of genes on
chromosomes 1 (CFH)57–60 and 10 (ARMS2/HTRA1)61–64. These
discoveries are remarkable because they are among the few
genetic associations for a common disease that increase the odds
of disease by more than 2.5 among heterozygotes and 7.5 among
homozygotes60,62. The association with CFH prompted focused
investigation of complement system genes27 which uncovered
associations with C3 65,66, BF/C2 67, and CFI 68.
Current research has focused on understanding the role of
specific genes and related pathways that drive AMD pathobiol-
ogy69–71. The genes identified in a recent GWAS highlight the
importance of both previously recognized and novel mechanistic
pathways including complement activation, collagen synthesis,
lipid metabolism/cholesterol transport, receptor-mediated endo-
cytosis, and extracellular matrix organization24. Variants located
in seven extracellular matrix genes were associated with advanced
AMD and not early/intermediate AMD, suggesting that extra-
cellular remodeling pathway(s) become relevant in advanced
disease72. Pathway analysis and systems biology approaches have
provided clues that upstream regulators/modulators of AMD risk
variants are potential therapeutic targets73,74. These approaches
give insight into the relationship between genetic variation and
disease mechanism that can be tested in appropriate in vivo and
in vitro models.
Except for CFH and HTRA/ARMS2, AMD-associated common
variants confer a very small effect on disease risk (i.e., odds ratios
<1.2), with as much as 70% of AMD risk remaining unex-
plained24. Increasing the samples for GWAS will undoubtedly
implicate more loci in addition to the 40+ already
identified24,25,70,75–77, but the associated variants will account
for an increasingly smaller amount of the genetic variance. A
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portion of the proverbial “missing heritability” may be the result
of gene interactions and environmental factors78,79. Associations
with highly penetrant rare variants in genes known to harbor
common variants have helped to establish causation, but the
extent that rare genetic variants with high impact will account for
the remaining genetic causality of AMD is unknown24,80–84. It
will be difficult to identify rare, highly penetrant alleles in novel
genes using traditional case–control designs because the requisite
sample size to detect rare variants is much greater than
aggregated cohorts assembled for GWAS. Nonetheless, such
discoveries will provide additional insight into disease
mechanisms.
Studies of non-European ancestry populations have demon-
strated variability in the strength of genetic associations for AMD
across Hispanics, Asians, and African Americans77,85. Protective
alleles may contribute to these population differences. For
example, AMD is very rare (<1%) in the isolated Timor-Leste
population, and the few affected individuals do not harbor risk
alleles at the two most associated AMD loci, CFH and ARMS2/
HTRA1 (ref. 86). However, the frequency of protective alleles at
CFH, CFHR2, and C2 was increased in Timorese compared to
outbred European ancestry populations, underscoring their
potential importance. It would be valuable to study cohorts in
which individuals with a high exposure to known AMD risk
factors (e.g., smoking), advanced age, and elevated genetic risk for
AMD do not develop AMD to gain insights into the protective
mechanisms of specific genes or pathways that might serve as
therapeutic targets.
Other types of genetic variants and mechanisms may have
important roles in dry AMD. These include copy number variants
or larger deletions and insertions, noncoding transcripts such as
lncRNAs and microRNAs as modulators of gene expression and
disease, and mitochondrial gene variants21,87. Somatic DNA
modifications resulting from environmental exposures such as
smoking and aging may also play a role in AMD
pathogenesis88,89. Germline and somatic DNA changes may not
directly impact pathogenic mechanisms, but rather influence
expression or interact with other genes that are more proximate
in pathways leading to disease. Thus, post-transcriptional DNA
modifications that alter expression and their downstream
consequences must be considered in studies that involve the
transcriptome, post-translational modifications, proteome, and
metabolome90. For example, using ATAC-Seq in the retina and
RPE from AMD and control patients, Wang et al.91 found global
decreases in chromatin accessibility in the RPE from early AMD
globes and in the retina of advanced disease, which suggests that
RPE dysfunction drives disease onset. Cigarette smoke treatment
of RPE cells recapitulated the chromatin accessibility changes
seen in AMD, providing a potential epigenetic link of a known
AMD risk factor with AMD pathology.
In vitro dry AMD models. The ability to differentiate embryonic
stem (ES) and induced pluripotent stem (iPS) cells into RPE cells
and retinal organoids has enhanced the ability to uncover the role
of specific pathways and genetic influences. The use of patient-
specific iPS cells is especially attractive because they have both the
specific gene mutation of interest and the underlying genotype
that could influence the mutation’s contribution to the patient’s
disease and phenotype. Galloway et al. studied iPS-derived RPE
cells from patients with and without AMD and found that sub-
RPE basal deposits were more abundant and contained a lipid-
and protein-rich “drusen-like” composition than unaffected
cells92. Saini et al.93 found that iPS-RPE cells derived from AMD
patients with the ARMS2/HTRA1 AMD risk variant had
increased complement and inflammatory proteins compared
donors without AMD. Saini et al.94 also found a graded response
to nicotinamide (NAM), with a marked inhibition of drusen-
associated proteins, clusterin and vascular endothelial growth
factor A, in iPS-RPE cells with the ARMS2/HTRA1 AMD
risk variant. These experiments underscore the importance of
targeting more than one disease pathway or mechanism at a time,
while taking into consideration genotype risk95. Alternatively, the
emergence of CRISPR/Cas9 gene editing has enabled researchers
to further manipulate stem cell systems for mechanistic study.
This approach can study the impact of a genetic variant by
comparing its behavior with an isogenic control cell line without
the mutation. With the possibility of personalized medicine, it
may be possible to predict a drug response using iPS-derived cells
or to differentiate iPS-derived retinal cells for transplantation into
a diseased macula.
Improved culturing techniques have enabled the generation of
retinal organoids. Using iPS cells, Zhong et al.96 recapitulated
spatiotemporally each of the main steps of retinal development
observed in vivo during the formation of three-dimensional
retinal cups that contain all major retinal cell types arranged in
their proper layers. Remarkably, the photoreceptors showed outer
segment formation and were photosensitive. This system can
enable the study of cellular interactions.
The use of iPS cells also has limitations. Due to heterogeneity
of iPS lines, a subclone could be selected that would misrepresent
the cell’s behavior. The epigenetic memory could remain and
maintain elements of the cell’s original phenotype. The relevance
of iPS cells to an aging disease such as AMD is open to
speculation since markers of cellular age, including mitochondrial
function and telomere length, are reset to a youth-like state after
old donor fibroblasts are reprogrammed to iPS cells97.
In vivo dry AMD models. To provide mechanistic evidence of
AMD pathobiology, zebrafish, mice, rats, and non-human pri-
mates are a few of the animals used to model AMD. The only
animal to possess a macula, non-human primates are prohibi-
tively expensive to maintain, and difficult to both manipulate and
follow longitudinally since their life span is long, outliving the
duration of most grants. Mice are the most practical organisms
for modeling AMD due to their short life span, genetic manip-
ulability, relatively low maintenance cost, and retinal architecture
that is similar to humans. The mouse does not possess a macula,
but rather a rod-rich retina that is similar to the rod-rich human
parafovea. While the lack of a macula has been used to question
their relevance to human AMD, mice have greatly aided our
understanding of AMD pathobiology. Despite this important
limitation, mice offer a valuable means of investigating the
interplay of aging, oxidative stress, immunity, lipid metabolism,
nutrition, and the microbiome as potential modifiers of retinal/
RPE disease43,98,99. Such studies cannot be done with in vitro
models and are not feasible in humans. However, most dry AMD
mouse models represent early disease stages. Advanced age is the
strongest risk factor for AMD and should be considered in any
model. In fact, the most robust AMD models incorporate
advanced age and are chronic in duration. Many AMD patho-
logical hallmarks have been recapitulated in different mouse
models, including vision loss; photoreceptor degeneration; RPE
lipofuscin accumulation, hypo- and hyperpigmentation, multi-
nucleation, and atrophy; choriocapillaris atrophy; and subretinal
immune cell infiltration43,100–103. However, few models faithfully
display a combination of these changes. While mice do not
develop drusen, they do accumulate basal laminar deposits, which
share many of the same constituents found in drusen43,100,102.
The models that most closely simulate human AMD are based on
known AMD-associated mechanisms, including inflammation,
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lipid transport and metabolism, ECM remodeling, complement
dysregulation, oxidative stress, and autophagy, which will enable
study of how these factors interact with one another during lesion
development, and how these lesions correlate with different stages
of dry AMD43,100,101. However, because of differences in anat-
omy, metabolism, and the immune response between mice and
humans, extrapolation to human disease should be made with
caution.
Clinical imaging of dry AMD. Imaging is an essential compo-
nent of the clinical assessment of AMD, and is used to diagnose,
define disease severity and progression, assess treatment response,
and complements mechanistic basic science analysis to under-
stand AMD pathobiology. Currently, color fundus photographs
are used to determine drusen size and total area, RPE pigmentary
abnormalities, and GA, with the aim to categorize and predict
AMD progression. Angiography with intravenously injected
sodium fluorescein or indocyanine green (ICG) dyes provides
detailed images of retinal and choroidal vasculature. Fundus
autofluorescence identifies areas with excess fluorophores from
RPE lipofuscin accumulation, loss of fluorophores from RPE loss,
or fluorophore variation104. Reflectance-based structural optical
coherence tomography (OCT), either spectral domain or the
faster swept source OCT, provides micron-level resolution to
enable detailed visualization of retinal layers, substructures, and
AMD pathology105. OCT-angiography can provide detailed
images of the choriocapillaris and choroidal abnormalities such as
choriocapillaris dropout with GA106. By registering images, spe-
cific OCT features can be monitored in the same location over
time to quantify morphologic progression107.
Several new imaging modalities may provide novel insight
into AMD pathobiology due to their ability to visualize key
cellular and subcellular structures during different disease
phases. Adaptive optics compensates for wave front aberrations
to improve resolution108. When used with a scanning laser
ophthalmoscope and OCT, adaptive optics systems can
visualize individual cones, changes in rods, RPE, and SDD in
dry AMD. Polarization-sensitive OCT highlights tissue using
polarized signals and birefringence so that the RPE or fibrosis
may be detected109. Fluorescence lifetime and hyperspectral
fluorescence imaging, which measure dynamic metabolic states
of the retina, offer new opportunities for retinal biomarkers that
may complement other functional methods such as psycho-
physical testing (such as dark adaptation thresholds and
kinetics) and electrophysiology110. These diagnostic tools may
identify preclinical risk factors or subtypes of AMD that may
differ with respect to progression and/or response to different
treatments.
However, validating these new imaging technologies either
individually or in combination has been restricted to small
cohorts over short or inconsistent follow-up intervals111,112.
Furthermore, imaging data have been simplified for clinical use,
which limits their utility to uncover a deep understanding of
AMD pathobiology. To advance our understanding, we must
identify imaging biomarkers of early changes that reflect AMD
pathobiology, predict disease progression and/or treatment
response, and correlate with molecular markers that are relevant
in both animal models and humans.
Recommendations for an expedited, improved
understanding, and clinical management of dry AMD
Cellular and animal dry AMD models enable direct interrogation
of pathological mechanisms in controlled environments, an
attribute obviously lacking in human studies. The question
remains of how to best leverage these models to determine the
role of AMD-associated mechanisms that will lead to effective
treatment. Cellular models are excellent for manipulating treat-
ments that alter intracellular interactions while animal models
enable the study of interactions among tissues, and how aberrant
pathways induce an AMD phenotype. Since many models are
incompletely or variably phenotyped, which can confuse inter-
pretation, we advocate developing a consensus on the phenotypic
standards of AMD animal models. This goal could be accom-
plished by a careful literature review on animal models that forms
the foundation for roundtable discussions by leading scientists
who utilize AMD animal models and clinicians who have
expertise in AMD imaging, epidemiology, and treatment.
Importantly, we recommend that animal and cell-based models
rely on multiple risk factors to mimic the events at different stages
of dry AMD, and that multiple models should be utilized to
deepen the rigor beyond what a single model will provide.
Systems biology approaches. So far, genetic and epidemiologic
studies have pinpointed more than 40 genetic variants and
environmental and lifestyle factors, such as smoking, sunlight
exposure, and a high-fat diet, that define individual risk for AMD.
Integrating such heterogeneous factors that influence AMD
pathobiology and turning this knowledge into prevention, pre-
diction, and treatment is a big challenge. The next step is to
understand the functional consequences of these risk factors.
Traditionally, interlinks between genetic and non-genetic factors
have been studied in a reductionist fashion. This approach is
insufficiently comprehensive to assign the relative contribution of
these risk factors to disease, the interaction of these factors, and
the disease stage that these factors are pathogenic. In contrast,
linking multiple data sources has already led to identifying the
alternative complement pathway, ECM turnover, and lipid
metabolism in AMD pathobiology113. The integration of genes
carrying risk alleles into the framework of complex endopheno-
types suggests that AMD risk genes act in multiple molecular
pathways and large networks, associate with different anatomical
microenvironments in the macula, and affect diverse higher order
physiological activities such as Bruch’s membrane homeostasis,
protein and lipid turnover, energy metabolism, and complement
regulation114. Thus, we recommend application of systems biol-
ogy to address the complex interplay of pathogenic factors and
provide the appropriate broad perspective needed to decipher the
role of multiple factors in dry AMD pathogenesis. This approach
would integrate basic, genomic, preclinical, medical, pharmaco-
logical, and clinical data into mathematical models of patholo-
gical processes at different stages of dry AMD in order to ask how
relevant individual components act together within the living
system. Research partnerships with companies that conduct dry
AMD clinical trials could provide valuable phenotyping infor-
mation that is required to assess disease progression and treat-
ment response that could be integrated with genetics and AMD
biomarkers. Furthermore, clinical trial participants should be
encouraged to maintain clinical follow-up after the study’s
completion and to consider donating their eyes after death for
research. While the effect of diet and environmental exposures on
the human microbiome and the implications of these changes on
the host immune and inflammatory systems have been explored
in AMD115, to gain a complete understanding of the complex
interactions and their role in the pathogenesis and progression of
dry AMD, all individual perturbations must be integrated into the
entire system to establish a causal role.
Imaging data provide the foundation for a systems biology
approach because they can identify the major pathological events
in chronological sequence. These images should provide objective
and reproducible longitudinal data that can be integrated with
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large multisystems data from large cohorts. The imaging data
must accurately co-localize morphologic changes in each of the
multiple imaging modalities, and individual patient data must be
cross-correlated before they can be incorporated into the overall
analysis. Deep learning will expand the capability of analyzing
these complex data sets116. To identify novel biomarkers, we
recommend using agnostic, artificial intelligence methods that are
independent of known biomarkers and/or prior categorizations to
both confirm known mechanisms and identify novel associations.
Because of the cost and scientific complexity of imaging
modalities, we acknowledge that the analysis of large cohorts of
imaging data may be limited to a few sites that are linked to a
wide net of collaborating centers.
The imaging data must be integrated with content-rich
clinical, epidemiological, pharmacological, and genetic data, as
well as multi-omic approaches including genomic, transcrip-
tomic, epigenomic, lipidomic, metabolomic, microbiome, and
proteomic studies on fresh blood, donor eye tissue, or aqueous
and vitreous biopsies from patients with dry AMD. Advances in
multi-scale data integration of large throughput experiments
and analysis have opened new avenues for discovery and have
bridged genetic risk variants with expression and protein level
information117,118. We recommend leveraging large data sets,
whether public or proprietary, that are now available including
those containing common and rare genetic variants for AMD,
transcriptomic data derived from the mouse and eventually
human retina, and proteomic data for developing a systems
biology model of dry AMD119. The emergence of single-cell
RNA and ATAC sequencing offers the possibility of defining
the relative contributions of individual cell types to AMD
pathogenesis, and will enrich the models that are developed.
Finally, pathogenic molecular pathways that have been inter-
rogated in cell and animal models must be integrated with these
data, which must be quality controlled and consistently curated.
These efforts require centralized and shared resources to
disseminate the information, and could provide an unprece-
dented resource to understand AMD pathobiology, re-define
stratified clinical phenotypes that are based on molecular and
dynamic parameters, develop combinatorial biomarkers or
biomarker signatures, and initiate novel diagnostic, prevention,
prediction, and therapeutic approaches where reductionist
approaches have failed.
The need for a personalized approach to treat dry AMD. Since
dry AMD is a multifactorial disease resulting from perturbations
in multiple pathways, the pathogenic signals are likely to vary
among individuals and at different disease stages. Thus, we
advocate designing computer models that are tailored to the
individual so that physicians can accurately predict dry AMD
risk, disease progression, and response to treatment. We believe
that this precision medicine approach for AMD, which was
unimaginable just a few years ago, is realistic and similar to what
is being achieved in other complex diseases such as cancer120 or
diabetes121. These individualized risk prediction models may
potentially enable targeting patients with specific dry AMD
subtypes for tailor-made therapies. Genomic and proteomic
biomarkers, and other risk factors identified from a systems
approach could monitor the effectiveness of preventive therapies
to modify dry AMD risk before the onset of vision-threatening
complications. Once single markers or marker signatures are
linked to specific stages and molecular mechanisms of AMD, they
can be employed as predictive or companion biomarkers and
biomarker signatures that hallmark specific pathogenic features
or pathological mechanisms of AMD. Having a set of multimodal
markers at hand to group and stratify patients according to their
individual risk and expected response pattern, therapeutic trials
tailored to specific patient groups could be designed. Individuals
within high-risk groups could be better motivated to comply with
an early intervention on the basis of a predicted cumulative risk
and a likely positive expected response to therapy prior to losing
vision. The prerequisite for this rationale, however, depends upon
the successful advancement of promising, preclinical drugs into
clinical trials.
Benefits and challenges of a systems biology approach for dry
AMD. This approach would be a departure from the current
research paradigm. Such an approach would require the inte-
grated collaboration of leading clinicians, imaging experts, a
wide variety of basic scientists, bioinformaticians, and biosta-
tisticians among other necessary expertise. Besides vision sci-
entists, this research will benefit by recruiting scientists outside
of dry AMD research who will provide not only additional
technical expertise, but potentially a “Medici effect” (i.e., the
most important innovations occur when concepts from diverse
disciplines are conjoined) where scientists without AMD
expertise could provide disruptive innovation that would
complement the conventional approach. Due to the perceived
cost, the clinical and basic science may be conducted at only a
few centers that have the appropriate infrastructure to imple-
ment this large-scale approach, or require coordinated efforts of
investigators at multiple institutions. However, implementing
large-scale team systems biology research should be possible.
We can now link heterologous large data sets to acquire novel
information on which to generate new hypotheses, calculate
risks on an individual basis, identify drivers of disease mani-
festation and progression, and turn knowledge into risk
assessment and clinical recommendations. The EYE-RISK
consortium is an example of how this goal can be achieved. A
consortium of participants from different European countries,
EYE-RISK (www.eye-risk.eu) funded by the EU Horizon 2020
program, uses a multidisciplinary approach to examine com-
prehensive epidemiologic data and biosamples from large
European epidemiologic eye cohorts and biobanks (total study
population N= 100,000). Collaborative studies conducted by
EYE-RISK, the International AMD Genomics Consortium, and
the Three Continent Consortium have been instrumental in
identifying genetic risk variants and assessing environmental
risk factors.
Currently, there is no organized, cost-effective system for
obtaining human donor globes that have short death-to-
dissection times with high-quality RNA, metabolite, DNA, and
protein that is adequate to meet the needs of the AMD research
community122. Likewise, the few existing repositories of blood or
ocular fluid samples from well-phenotyped patients for study are
not sufficiently resourced to distribute specimens on a wide scale.
To enable this systems approach, we recommend developing
mechanisms to create these libraries of AMD eyes, blood and
ocular fluid samples, an array of omics data (e.g., genomic,
transcriptomic, methylomic, proteomic, etc.) derived from these
samples, and a program that ensures their effective use for dry
AMD research. The National Cell Repository for Alzheimer
disease which banks blood and DNA specimens, brain tissue, and
associated data for Alzheimer disease research (https://www.nia.
nih.gov/research/resource/national-cell-repository-alzheimers-
disease-ncrad) is one example of a coordinated approach to
address this need.
The current National Eye Institute and foundation-based
funding mechanisms for AMD research are largely confined to
grants awarded to individual researchers for a defined amount of
money. This approach, which has been the cornerstone of our
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current understanding of AMD pathobiology to date, enables
researchers to address specific, focused mechanistic questions, but
in relative isolation. A systems biology approach using sophis-
ticated high-throughput “-omics” assays is not feasible with a
typical individual R01 NIH grant. We recommend that the NIH
and other funding agencies examine how they allocate precious
resources and consider including large programs that would
enable the integration of basic discovery research, mechanistic
investigation using well-phenotyped human populations, and
suitable animal and cell-based models that are needed to gain a
detailed understanding of dry AMD pathobiology. Mechanisms
that foster access and coordination of multiple investigators to
resources that would not be achievable on an individual basis
would address this next step in dry AMD research. The
implementation of this approach could be a template for tackling
other complex diseases.
Conclusion
Future directions in dry AMD research should emphasize systems
biology approaches that integrate omic, pharmacological, and
clinical data into mathematical models that can predict disease
onset and progression, identify biomarkers, establish disease
causing mechanisms, and monitor response to therapy. Success in
these areas will likely be achieved most expediently and effectively
by promoting collaborative efforts of multidisciplinary investi-
gator teams and developing centralized resources including
clinical, imaging, omic, and other types of data as well as carefully
phenotyped eye tissue from large cohorts of patients with and
without AMD.
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